Hereditary hemorrhagic telangiectasia and biological therapeutics — the development of targeted anti-angiogenic treatments (bevacizumab, pazopanib, thalidomide, sirolimus) specifically addressing the underlying vascular abnormality driving the severe recurrent epistaxis of HHT — representing the most scientifically innovative therapeutic development within the Epistaxis Market, with...